KRAS and Miyoshi myopathy: For example, since we just tested the therapeutic effects of SHP2 inhibitors in RPMI-8226 and NCI-H929 cells, which express activated N-Ras or K-Ras (Bolick et al., 2003), further efforts should be applied to compare the efficacy of the SHP2 inhibitors in Ras wild-type vs. mutant MM cell lines in future.